Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | FPR1 | P21462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2370559 | 0.91 | BACE1 (0.36) | BACE1CTSDTAAR1 | |
| SCHEMBL2370624 | 0.82 | BACE1 (0.34) | BACE1 | |
| SCHEMBL2370839 | 0.81 | BACE1 (0.37) | BACE1APPCTSDMEN1CYP3A4 | |
| SCHEMBL12471311 | 0.81 | BACE1 (0.33) | BACE1 | |
| SCHEMBL2370936 | 0.77 | BACE1 (0.35) | BACE1APPMEN1CYP3A4CYP2D6 | |
| SCHEMBL2371239 | 0.76 | MEN1 (0.36) | BACE1MEN1KMT2A | |
| SCHEMBL2370773 | 0.74 | BACE1 (0.36) | BACE1CTSD | |
| SCHEMBL2370457 | 0.73 | BACE1 (0.59) | BACE1CTSD | |
| SCHEMBL2370464 | 0.73 | BACE1 (0.59) | BACE1CTSD | |
| SCHEMBL2370905 | 0.73 | BACE1 (0.59) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777019-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9725469-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160159818-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9346827-B2 | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use | AMGEN INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9296759-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150307521-A1 | AMINO-OXAZINE AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2015-10-29 | — | — | US | disclosed |
| US-9012446-B2 | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140296226-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. | 2014-10-02 | — | — | US | disclosed |
| EP-2758406-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2014078314-A1 | AMINO-OXAZINE AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20140045828-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2014-02-13 | — | — | US | disclosed |
| US-20140031340-A1 | 5-Amino-Oxazepine and 5-Amino-Thiazepane Compounds as Beta Secretase Antagonists and Methods of Use | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2547686-B1 | AMINO-DIHYDROOXAZINE AND AMINO-DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA-SECRETASE MODULATORS AND THEIR MEDICAL USE | AMGEN INC (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2673279-A1 | 5-AMINO-OXAZEPINE AND 5-AMINO-THIAZEPANE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | Amgen Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8497264-B2 | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| WO-2013044092-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| EP-2547686-A1 | AMINO -DIHYDROOXAZINE AND AMINO - DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA - SECRETASE MODULATORS AND THEIR MEDICAL USE | Amgen Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| WO-2012109165-A1 | 5-AMINO-OXAZEPINE AND 5-AMINO-THIAZEPANE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| US-20110251186-A1 | Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115928-A1 | AMINO -DIHYDROOXAZINE AND AMINO - DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA - SECRETASE MODULATORS AND THEIR MEDICAL USE | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296226-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, APP, BACE2 | BACE1 1/4885APP 2/4885CTSD 2116/4885 |
| US-20160159818-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, APP, BACE2 | BACE1 1/4885APP 2/4885CTSD 2039/4885 |
| US-20140045828-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, APP, BACE2 | BACE1 1/4885APP 2/4885CTSD 1985/4885 |
| US-20140031340-A1 | 5-Amino-Oxazepine and 5-Amino-Thiazepane Compounds as Beta Secretase Antagonists and Methods of Use | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885CTSD 976/4885 |
| US-20110251186-A1 | Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, APP, BACE2 | BACE1 1/4885APP 2/4885CTSD 1985/4885 |
| US-20150307521-A1 | AMINO-OXAZINE AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, APP, BACE2 | BACE1 1/4885APP 2/4885CTSD 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.